Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Manufacturing
  • Multispecifics are transforming the CDMO development architecture
  • Manufacturing

Multispecifics are transforming the CDMO development architecture

BioSpace

Manufacturers are being pushed beyond mAbera platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.

Read full story

pharminent August 28, 2026 (Last updated: September 1, 2026)

BioSpace

Manufacturers are being pushed beyond mAbera platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing.

Read full story

Post navigation

Previous: FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis
Next: FDA green lights Priovant drug for rare skin disease

Related Stories

  • Manufacturing

Samsung Biologics inks $262M manufacturing deal with European pharma company

pharminent September 11, 2026
  • Manufacturing

Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision

pharminent September 9, 2026
  • Manufacturing

US puts $125m into personalised RNA therapy production

pharminent September 2, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.